MSK-HemePACT panel

Overview

MSK-HemePACT is a Memorial Sloan Kettering targeted hybrid-capture DNA sequencing panel focused on hematologic malignancies, covering ~585 cancer-associated genes. It is the heme-focused counterpart to MSK-IMPACT and is used on tumor biopsies, matched germline, and CSF ctDNA PMID:38995739.

Used by

• PMID:38995739 — applied to archival tumor (25/31 PCNSL) and paired pre-/on-treatment CSF ctDNA (14 patients) in a phase I/II ibrutinib trial in r/r CNS lymphoma; identified TBL1XR1 WD40-domain mutations as associated with prolonged ibrutinib PFS (16.5 vs 3.1 months, p=0.0075), and enabled CSF ctDNA kinetic analysis showing that ctDNA clearance within 4 weeks correlated with complete and long-term response PMID:38995739.
• PMID:38497151 — MSK-IMPACT Heme (hybridization capture-based 400-gene panel detecting SNVs, small INDELs, and CNAs) used to sequence 396 DLBCL cases; LymphGen classification applied to IMPACT Heme variants + FISH data achieved 92% accuracy vs comprehensive NCI panel PMID:38497151.

Notes

• ~585 cancer genes, hematologic-focused; used on both tumor tissue and CSF ctDNA with matched germline PMID:38995739.
• Corpus-grown slug; not present in canonical schema/ontology/gene_panels.json, so marked unverified: true.

Sources

• PMID:38995739
• PMID:38497151

This page was processed by entity-page-writer on 2026-04-11.